CHEC PR

CHEC PR has developed orally available peptide compounds for cell degeneration due to inflammation, oxidative stress or protein aggregation. The goal of the organization is to extend a large volume of animal data, showing excellent efficacy in neurodegenerative models, to the modeled human diseases. Possible lead indications for which there are proof of concept data: Multiple Sclerosis, Alzheimer’s and/or Parkinson’s Disease, Central Nervous System Injuries, and Seizure Disorders. There is v... ery limited industry progress for the above indications. The current treatments for MS relapse are by injection with no long term benefit for neurodegeneration and disability and highly variable safety profiles. No combined anti-inflammatory or aggregate disposal therapies are presently available for neurodegenerative disorders like Alzheimer’s, Parkinson’s, or Huntington’s diseases. CHECs are unique because they target all the principal cellular pathologies in degenerative diseases (inflammation, cell death, protein aggregation) in an orally available formulation. Company advisors are Timothy Cunningham, Ph.D., who discovered and isolated the compounds, and Jeffrey Greenstein, M.D., who is a neurologist/immunologist that will supervise clinical applications. The peptides are protected by issued US patents and several patent applications. CHEC PR takes a flexible position for selection of initial lead indication and for equity sharing. Accommodating investor interest and needs in this way is expected to expedite capitalization and clinical development, Key Milestones: - Selection of lead indication - IND enablement thru Phase I Summary: CHEC PR has a highly qualified team of advisors that have developed these novel peptide therapeutics with potential is in several multi-billion dollar markets. The peptide is orally available, CNS penetrant, with no demonstrated safety concerns .More